Bimekizumab for the Treatment of Psoriasis: A Review of the Current Knowledge

Bimekizumab, a novel humanized monoclonal IgG1 antibody that neutralizes both IL-17A and IL-17F, was recently approved the treatment of moderate to severe plaque psoriasis in adults who are candidates for systemic therapy. Bimekizumab represents the latest anti IL-17 treatment available for the mana...

Descripción completa

Detalles Bibliográficos
Autores principales: Ruggiero, Angelo, Potestio, Luca, Camela, Elisa, Fabbrocini, Gabriella, Megna, Matteo
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Dove 2022
Materias:
Review
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9189155/
https://www.ncbi.nlm.nih.gov/pubmed/35707807
http://dx.doi.org/10.2147/PTT.S367744

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9189155/
https://www.ncbi.nlm.nih.gov/pubmed/35707807
http://dx.doi.org/10.2147/PTT.S367744

Ejemplares similares